Drug development company Poolbeg Pharma (AIM: POLB) (OTCQB: POLBF) announced on Tuesday that it has entered into a strategic collaboration with a Nasdaq-listed biopharma company to develop an optimized oral drug for a metabolic condition using Poolbeg's licensed oral delivery technology.
The agreement includes funding for producing a prototype drug, aiming to enhance the delivery of the partner's novel drug to its therapeutic site. Poolbeg is optimistic about the collaboration evolving into a full licensing agreement, integrating the oral delivery technology into the biopharma's pipeline. This collaboration signifies a crucial step for Poolbeg towards early revenues and reinforces its commitment to advancing treatments for metabolic conditions.
Poolbeg Pharma specialises in innovative medicines for infectious and prevalent diseases, employing a disciplined portfolio approach to accelerate drug development. The company targets the growing infectious disease market, which is projected to exceed USD250bn by 2025.
With access to assets from hVIVO plc, Poolbeg leverages over 20 years of human challenge trial data, progressing programs in oncology and metabolic syndromes. Notable assets include POLB 001, a small molecule immunomodulator for severe influenza, POLB 002, an intranasally administered RNA-based immunotherapy and POLB 003, a vaccine candidate for Melioidosis. Poolbeg Pharma utilizes AI for target identification, asset acquisition and pipeline expansion, showcasing a diverse and promising portfolio.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
AstraZeneca increases dividend by 7%
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
Wolters Kluwer enhances Clinical GenAI leadership with AI Labs powered by UpToDate
Amgen announces share dividend for Q2 2024
Virbac expands presence in Japan with Sasaeah acquisition
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva